Advertisement
Canada markets open in 27 minutes

  • S&P/TSX

    24,822.54
    +132.04 (+0.53%)
     

  • S&P 500

    5,864.67
    +23.20 (+0.40%)
     

  • DOW

    43,275.91
    +36.81 (+0.09%)
     

  • CAD/USD

    0.7235
    -0.0013 (-0.17%)
     

  • CRUDE OIL

    70.40
    +1.18 (+1.70%)
     

  • Bitcoin CAD

    94,159.52
    -202.63 (-0.21%)
     

  • XRP CAD

    0.76
    +0.02 (+2.18%)
     

  • GOLD FUTURES

    2,752.70
    +22.70 (+0.83%)
     

  • RUSSELL 2000

    2,276.09
    -4.76 (-0.21%)
     

  • 10-Yr Bond

    4.1320
    +0.0590 (+1.45%)
     

  • NASDAQ futures

    20,403.75
    -79.75 (-0.39%)
     

  • VOLATILITY

    19.04
    +1.01 (+5.60%)
     

  • FTSE

    8,333.95
    -24.30 (-0.29%)
     

  • NIKKEI 225

    38,954.60
    -27.15 (-0.07%)
     

  • CAD/EUR

    0.6662
    -0.0004 (-0.06%)
     
MARKETS LIVE BLOG:

NASDAQ FUTURES LEAD STOCKS LOWER IN WAIT FOR MORE EARNINGS

Earnings season ramps up this week, as over 100 S&P 500 companies are lined up to report

UniQure: Q2 Earnings Snapshot

Associated Press Finance
·1 min read

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Thursday reported a loss of $56.3 million in its second quarter.

On a per-share basis, the Amsterdam-based company said it had a loss of $1.16.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share.

The human gene therapy company posted revenue of $11.1 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $3.5 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on QURE at https://www.zacks.com/ap/QURE